References & Citations For Essential Health Tests Before Your First Weight Loss Shot
-
American Diabetes Association (ADA). (2022). Standards of Medical Care in Diabetes—2022. Diabetes Care, 45(Suppl 1): S1–S264.
-
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., & Gibbons, C. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251.
-
Davies, M. J., Bergenstal, R., Bode, B., et al. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA, 314(7), 687-699.
-
Drucker, D. J., & Nauck, M. A. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 368(9548), 1696-1705.
-
Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.
-
Garber, A. J., Handelsman, Y., Grunberger, G., et al. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocrine Practice, 26(1), 107-139.
-
Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409-1439.
-
Khalil, A. A., Mohktar, M. S., Sulaiman, S. A., & Ibrahim, F. (2021). The impact of GLP-1 receptor agonists on nutrient intake and nutritional status. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(4), 102200.
-
Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.
-
Müller, N., Dicker, D., Atkin, S., & Tsapas, A. (2019). Effects of GLP-1 receptor agonists on renal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Research and Clinical Practice, 155, 107804.
-
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
-
Sjölund, K., Torgerson, J. S., & Carlsson, L. M. S. (2014). Gallstone disease and its association with weight loss: results from a randomized controlled trial of obesity treatment. American Journal of Gastroenterology, 109(8), 1222-1229.
-
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.


